Search Results

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2024.

Infertility Is a Common Struggle for Both Sexes. The Innovative French Health Brand Gynov Is Addressing This Concern with Myo-Inositol.

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”) today announced that it will report financial results for the fourth quarter and fiscal year ended December 31, 2023 on March 7, 2024.

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the first quarter ended March 31, 2024 on May 8, 2024.

MYOS CORP (“MYOS” or the “Company”), is a research-based advanced nutrition company with divisions that address both Human Nutrition and Animal Health . MYOS is the sole owner of Fortetropin ® , a proprietary advanced nutrition product developed and owned by MYOS, that has been shown in multiple veterinary and human cli

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, chairman and chief executive officer and David Henry, chief financial officer, will present and host one-on-one meetings with investors at the Sidoti Virtual Investor conference being held on June 12-13, 2024.

After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are back together with a mission to make cardiovascular disease curable and preventable.

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months and year ended December 31, 2023.

Seven prestigious thought leaders from private practice and academia will guide MYOS CORP through its next stage of growth in animal health industry

As previously announced, on June 30, 2020, MYOS RENS Technology, Inc., a Nevada corporation (“MYOS”), and MedAvail, Inc., a privately-held Delaware corporation (“MedAvail”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), by and among MYOS, MedAvail,